This was posted earlier today (Tuesday):
Geron Corporation (Nasdaq:GERN) today announced that its IND
(Investigational New Drug application) for GRNOPC1, a cell therapy for
neurologically complete, subacute spinal cord injury, has been placed on
clinical hold by the FDA pending the agency’s review of new nonclinical
animal study data submitted by the company. A clinical hold is an order
that the FDA issues to a sponsor to delay a proposed trial or to suspend
an ongoing trial.
Read the complete announcement.
We have posted on this trial in the past -
Read The whole world is watching and
Ethical concerns about SCI clinical trials.
Rob
Anonymous comments are disabled
About gerthro
I lived all my life in and around the Philadelphia area. Went to Temple University, taught television production at Plymouth Whitemarsh high school. In the meantime, I've had lots of jobs in television and multimedia. I left my position as the managing editor of MensHealth.com to come to the Reeve Foundation as the manager of online communications in 2007.
